In February of 2006 the Food and Drug Administration issued a public health advisory for doctors who perform heart bypass surgery and their patients concerning the potential serious side-effects of Trasylol. Trasylol is the only drug approved by the FDA for the prevention of peri-operative blood loss and the need for blood transfusion among patients undergoing coronary artery bypass graft surgery.
Read the FDA Public Health Advisory Concerning Trasylol
An FDA Alert was issued in December of 2006 for Aprotinin Injection marketed as Trasylol. This alert covered the new prescription revisions and new labeling for the drug. This alert also warned against renal dysfunction.
Pharmaceutical Litigation Attorneys at Bailey & Galyen have extensive experience in cases involving injury or wrongful death associated with prescription drugs. Contact us to set an appointment with an attorney to discuss your case.